Resource Details

Title

Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients (Review)

Author(s)EM Hodson; CA Jones; GFM Strippoli; AC Webster; JC Craig.
AbstractProphylaxis with Immunoglobulin G (IgG), anti CMV vaccine or interferon do not significantly reduce CMV disease and CMV-associated mortality in solid organ transplant recipients.

Cytomegalovirus (CMV) is the most common virus causing disease and death in solid organ transplant recipients (kidney, heart, liver, lung and pancreas) during the first six months after transplantation. This review looked at the benefits and harms of IgG, anti CMV vaccines and interferon to prevent CMV disease in solid organ transplant recipients. Thirty seven trials (2185 participants) were identified. This review shows that IgG did not reduce the risk of CMV disease or all-cause mortality compared with placebo or no treatment. The combination of IgG with antiviral medications (aciclovir or ganciclovir) were not more effective than antiviral medications alone in reducing the risk of CMV disease or all-cause mortality. Anti CMV vaccines and interferon did not reduce the risk of CMV disease compared with placebo or no treatment. Currently there are no indications for IgG in the prevention of CMV disease in recipients of solid organ transplants.
Date of publishing04/18/2007
Date of last review by us07/28/2007
Bookmark this page Email this page to a friend Print this page




Review










 





Twitter FeedTwitter Feed